New York: Nektar Therapeutics (NASDAQ:NKTR)’s Stock Had Its Buy Rating Restated at Roth Capital in Report Issued Today. Has $31.0 Target

Share with your friends










Submit

Roth Capital Analyst Rating Change Nektar Therapeutics NASDAQ:NKTR

Nektar Therapeutics (NASDAQ:NKTR) Rating Reconfirmed

The company have set target of $31.0 on Nektar Therapeutics (NASDAQ:NKTR) shares. This is 100.00 % from the last stock close price. In a research report revealed to investors and clients on Monday, 20 March, Roth Capital restate their Buy rating on shares of NKTR.

NASDAQ:NKTR is currently trading 43.29% higher at $22.21 as of 8:05 AM New York time. Nektar Therapeutics’s stock is 0% in the last 200 days. It has underperformed the S&P500 Index, which has increased 13.29% in the same time.

Institutional Ownership

Ra Capital Management Llc had the most significant stake with ownership of 3.66 million shares as of Q2 2015 for 6.49% of the long stock exposure. Bridger Management Llc is another bull as the investment manager who is possessing 2.83 million shares of Nektar Therapeutics or 3.28% of their long stock exposure. In addition, Camber Capital Management Llc have 2.42% of their long stock exposure invested in the company for 3.20 million shares. The Florida-based fund Harvey Capital Management Inc revealed it had acquired so far a stake worth about 2.03% of the investment manager’s stock portfolio in Nektar Therapeutics. The New York-based fund Opus Point Partners Management Llc is also positive about the stock, possessing 382,250 shares or 1.7% of their long stock exposure.

Nektar Therapeutics (NASDAQ:NKTR) Profile

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology.

Nektar Therapeutics (NASDAQ:NKTR) traded up 43.29% on 20 March, hitting $22.21. A total of 15.31M shares of the company’s stock traded hands. This is up from average of 1.41M shares. Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $22.32. The company has a market cap of $3.37B and a P/E ratio of 0.

Get the latest Nektar Therapeutics (NASDAQ:NKTR) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.